Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


EU Looks At New Ways To Tackle Antibiotic Market Failure

Exclusivity Vouchers And Fee Waivers Under Consideration

Executive Summary

A novel Swedish payment scheme and transferable exclusivity vouchers for new antimicrobials are among mechanisms being examined by the European Commission for encouraging the development of new drugs to tackle the growing problem of antibiotic resistance. 

You may also be interested in...

New AMR Report Is ‘A Wake-Up Call’, Says Industry Body

Another day, another report on how to tackle the ever-present problem of antimicrobial resistance and the dearth of new treatment. In its latest assessment of the state of play, the AMR Industry Alliance has come up with some alarming facts and figures – and some ideas for the next steps.

UK Plans Upfront Payment Scheme To Spur Antimicrobial Development

A new UK project will look at the potential of upfront payments to encourage companies to invest in the development of new antimicrobial drugs. The scheme, developed by NICE and NHS England, will use a tailored health technology assessment approach and is seen as a possible model for other countries to emulate in the fight against antimicrobial resistance. 

Hungary Breaks Ranks With EU & Authorizes Use Of AstraZeneca Vaccine

Hungary is going its own way when it comes to coronavirus vaccines, but its decision to allow the emergency use of the Oxford University/AstraZeneca vaccine may be only a symbolic expression of the government’s growing impatience with the EU.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts